PaxMedica, Inc. (PXMD) AI Stock Analysis

• Market Cap: $1.09K
• Dividend Yield: N/A
• Average Volume (3M): 37.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 65.64
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.88
• Shares Outstanding: 10,879,170
• 10 Day Avg. Volume: 1,549
• 30 Day Avg. Volume: 37,622
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

PaxMedica's significant financial challenges, including no revenue and negative cash flows, weigh heavily on its stock score. Technical indicators suggest a bearish trend, and valuation metrics are poor with a negative P/E ratio. The lack of guidance or highlights from the earnings call provides limited insight into future prospects, resulting in a low overall score.

PaxMedica, Inc. Business Overview & Revenue Model

Company Description

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

How the Company Makes Money

PaxMedica, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around advancing its clinical pipeline through various stages of research and development, with the ultimate goal of obtaining regulatory approval and bringing its therapies to market. Revenue streams may include upfront payments, milestone payments, and royalties from potential partnerships or licensing agreements with larger pharmaceutical companies. Additionally, PaxMedica may seek funding through grants and collaborations to support its research initiatives. However, as a clinical-stage company, it may not yet generate significant revenue from product sales until its therapies reach commercialization.

PaxMedica, Inc. Financial Statement Overview

Summary

PaxMedica, Inc. faces significant financial challenges with no revenue generation, consistent net losses, and negative cash flows. While improvements in equity position and no debt reduce some financial risk, the company needs to focus on revenue generation and operational efficiency.

Income Statement

PaxMedica, Inc. has reported no revenue over the past five years, which is concerning for long-term growth prospects. Consistent net losses over the years reflect challenges in achieving profitability, with the latest net income being significantly negative. The lack of revenue growth and negative profit margins indicate a need for strategic changes.

Balance Sheet

The company has improved its stockholders' equity from a negative position in prior years to a positive balance, which is a positive development. However, the absence of revenue and a low equity ratio suggest limited asset utilization. The company maintains no debt, reducing financial risk, but the overall balance sheet strength is moderate due to low asset levels.

Cash Flow

Operating activities consistently result in negative cash flows, highlighting inefficiencies in core operations. Free cash flow remains negative, indicating the company is not generating cash to cover its expenditures. The reliance on financing activities suggests potential liquidity concerns if external funding becomes unavailable.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-16.14M	-16.51M	-7.20M	-5.62M	-599.00K
Net Income	-18.29M	-14.80M	-13.04M	-8.49M	-599.00K
Balance Sheet
Total Assets	5.68M	2.20M	648.87K	1.12M	24.95K
Cash, Cash Equivalents and Short-Term Investments	4.71M	1.90M	444.09K	1.12M	24.95K
Total Debt	0.00	173.54K	0.00	611.64K	0.00
Total Liabilities	2.30M	2.10M	10.76M	5.75M	123.25K
Stockholders Equity	3.39M	108.80K	-10.11M	-4.63M	-98.30K
Cash Flow
Free Cash Flow	-10.77M	-6.07M	-5.51M	-2.35M	-419.38K
Operating Cash Flow	-10.77M	-6.07M	-5.51M	-2.35M	-419.38K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	13.58M	7.53M	4.83M	3.45M	435.00K

PaxMedica, Inc. Technical Analysis

• Last Price: 0.03

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PXMD, the sentiment is undefined. The current price of 0.03 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for PXMD.

PaxMedica, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	78 Outperform	14.40B	42.87	12.93%	―	18.42%	1.47%
MNKD	63 Neutral	1.67B	49.68	-59.59%	―	21.48%	162.30%
AVXL	62 Neutral	726.66M	-14.93	0.00%	―	0.00%	-13.05%
BTAI	37 Underperform	43.52M	-0.24	0.00%	―	-63.88%	77.72%
PXMD	32 Underperform	$1.09K	―	-540.31%	―	―	―
SHPH	32 Underperform	4.38M	-0.07	0.00%	―	0.00%	31.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%